FDA Brief

Warning letters Drugs

FDA warning letter to

Klarity Kratom

High riskIssued Jun 30, 2022Posted Jul 5, 2022Center for Drug Evaluation and Research | CDER

Klarity Kratom sold kratom products as unapproved drugs claiming they treat opioid addiction, FDA and FTC say.

What happened

FDA reviewed the website https://klaritykratom.com/ on May 31, 2022, and the Federal Trade Commission reviewed it in June 2022, and both found the company takes orders there for kratom products. The site carried claims that kratom eases opioid withdrawal, removes opioid effects, and helps rheumatoid arthritis symptoms, plus a customer review about giving up opioids. FDA says those claims make the products unapproved new drugs, and FTC says the addiction claims lack scientific support.

What FDA found

  1. The website claims kratom treats opioid withdrawal, opioid addiction and arthritis symptoms, which makes the products drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The products are not generally recognized as safe and effective for these uses, so they count as new drugs.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The company sells these new drugs without an FDA-approved application, which is illegal.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  4. The company advertises that kratom can treat or cure opioid addiction without competent and reliable scientific evidence, which the FTC Act forbids.

    FTC Act, 15 U.S.C. 41-57
  5. Deceptive claims about treating a substance use disorder can bring civil penalties of up to $46,517 per violation plus consumer refunds.

    Section 8023 of the Opioid Addiction Recovery Fraud Prevention Act of 2018, 15 U.S.C. 45d

What FDA wants

FDA asks the company to write within 15 working days describing the specific steps taken to correct the violations and prevent recurrence, with supporting documents. FTC separately demands that the company immediately stop all addiction-treatment claims and report its actions to FTC within 15 working days.

Who should pay attention

  • kratom brands and online retailers that make health claims
  • marketers of herbal or botanical products claiming addiction or disease benefits
  • e-commerce and payment platforms hosting such product listings

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk